Nose-to-brain drug delivery method works in early trial

04/18/2013 | Xconomy

Impel Neuropharma's nose-to-brain drug delivery method sent a small peptide molecule into the brain in a seven-patient trial, the company's chief scientist said. The technology could have applications in central nervous system disorders and pain relief. Angel investors, the NIH, the Pentagon and Washington state's Life Sciences Discovery Fund provided support for the project.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA